Effects of 3-month liraglutide treatment on oxidative stress and inflammation in type 2 diabetes patients with different urinary albumin-to-creatinine ratio categories.

Chen S, He M, Qin Y, Tian J, Liang Z, Li Y, Wang P, Zhang Y, Zhou C, Xiao J

Medicine1 Nov 2024Cited by 2 (Europe PMC)

PMID39809212PMCIDPMC11596640DOI10.1097/md.0000000000040438PepBankPUB-39809212

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study13

12 results from studies that gave the peptide. 12 results from people.

01HumanObservational studyEfficacy outcome
In adults with type 2 diabetes starting liraglutide, body mass index fell significantly after 3 months in all 3 UACR groups.
In plain wordsIn adults with type 2 diabetes, body mass index fell after 3 months of liraglutide, whatever their kidney protein-leak level.
Peptide
Liraglutide
Outcome
DecreaseBody mass index change
Study
n = 107
Comparator
Baseline (before treatment)
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
After 3-month liraglutide treatment, fasting plasma glucose, glycated hemoglobin, and body mass index significantly decreased in all 3 groups regardless of the baseline UACR (all P < .05).
2 context sentences(design, population, supporting numbers)
Summary · context
We enrolled 107 patients with T2D who were initiating liraglutide for glycemic control.
Summary · context
Patients were categorized into 3 groups: group I (UACR 300 mg/g).
Report a problemFND-3980921201
02HumanObservational studyEfficacy outcome
In adults with type 2 diabetes starting liraglutide, fasting plasma glucose fell significantly after 3 months in all 3 UACR groups.
In plain wordsIn adults with type 2 diabetes, fasting blood glucose fell after 3 months of liraglutide in every kidney-protein-leak group.
Peptide
Liraglutide
Outcome
DecreaseFasting plasma glucose change
Study
n = 107
Comparator
Baseline (before treatment)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
After 3-month liraglutide treatment, fasting plasma glucose, glycated hemoglobin, and body mass index significantly decreased in all 3 groups regardless of the baseline UACR (all P < .05).
2 context sentences(design, population, supporting numbers)
Summary · context
We enrolled 107 patients with T2D who were initiating liraglutide for glycemic control.
Summary · context
Patients were categorized into 3 groups: group I (UACR 300 mg/g).
Report a problemFND-3980921202
03HumanObservational studyEfficacy outcome
In adults with type 2 diabetes starting liraglutide, glycated hemoglobin fell significantly after 3 months in all 3 UACR groups.
In plain wordsIn adults with type 2 diabetes, HbA1c fell after 3 months of liraglutide in every kidney-protein-leak group.
Peptide
Liraglutide
Outcome
DecreaseGlycated hemoglobin change
Study
n = 107
Comparator
Baseline (before treatment)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
After 3-month liraglutide treatment, fasting plasma glucose, glycated hemoglobin, and body mass index significantly decreased in all 3 groups regardless of the baseline UACR (all P < .05).
2 context sentences(design, population, supporting numbers)
Summary · context
We enrolled 107 patients with T2D who were initiating liraglutide for glycemic control.
Summary · context
Patients were categorized into 3 groups: group I (UACR 300 mg/g).
Report a problemFND-3980921203
04HumanObservational studyEfficacy outcome
In adults with type 2 diabetes and microalbuminuria or macroalbuminuria, UACR fell significantly after 3 months of liraglutide.
In plain wordsIn adults with type 2 diabetes and raised urine albumin, liraglutide was followed by a lower urine albumin-to-creatinine ratio.
Peptide
Liraglutide
Outcome
DecreaseUACR change in groups II and III
Study
n = 107
Comparator
Baseline (before treatment)
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
UACR significantly decreased in groups II (P = .005) and III (P = .001).
2 context sentences(design, population, supporting numbers)
Summary · context
We enrolled 107 patients with T2D who were initiating liraglutide for glycemic control.
Summary · context
Patients were categorized into 3 groups: group I (UACR 300 mg/g).
Report a problemFND-3980921204
05HumanObservational studyEfficacy outcome
In adults with type 2 diabetes on liraglutide, patients with higher baseline UACR showed a significantly greater albuminuria reduction.
In plain wordsIn adults with type 2 diabetes on liraglutide, people with more urine albumin at the start had a bigger drop in it.
Peptide
Liraglutide
Outcome
DecreaseAlbuminuria reduction by baseline UACR
Study
n = 107
Comparator
Baseline (before treatment)
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
Patients with higher UACR at baseline showed significantly greater albuminuria reduction (P < .001).
2 context sentences(design, population, supporting numbers)
Summary · context
We enrolled 107 patients with T2D who were initiating liraglutide for glycemic control.
Summary · context
Patients were categorized into 3 groups: group I (UACR 300 mg/g).
Report a problemFND-3980921205
06HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, serum TNF-α fell significantly after 3 months of liraglutide in all 3 UACR groups.
In plain wordsIn adults with type 2 diabetes, the inflammation marker TNF-α fell after 3 months of liraglutide.
Peptide
Liraglutide
Outcome
DecreaseTNF-α change
Study
n = 107
Comparator
Baseline (before treatment)
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
Compared with baseline, TNF-α, IL-6, MCP-1, and MDA were remarkably decreased, while SOD and glutathione peroxidase were significantly increased in all 3 groups (P < .05).
2 context sentences(design, population, supporting numbers)
Summary · context
We enrolled 107 patients with T2D who were initiating liraglutide for glycemic control.
Summary · context
Patients were categorized into 3 groups: group I (UACR 300 mg/g).
Report a problemFND-3980921206
07HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, serum IL-6 fell significantly after 3 months of liraglutide in all 3 UACR groups.
In plain wordsIn adults with type 2 diabetes, the inflammation marker IL-6 fell after 3 months of liraglutide.
Peptide
Liraglutide
Outcome
DecreaseIL-6 change
Study
n = 107
Comparator
Baseline (before treatment)
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
Compared with baseline, TNF-α, IL-6, MCP-1, and MDA were remarkably decreased, while SOD and glutathione peroxidase were significantly increased in all 3 groups (P < .05).
2 context sentences(design, population, supporting numbers)
Summary · context
We enrolled 107 patients with T2D who were initiating liraglutide for glycemic control.
Summary · context
Patients were categorized into 3 groups: group I (UACR 300 mg/g).
Report a problemFND-3980921207
08HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, serum MCP-1 fell significantly after 3 months of liraglutide in all 3 UACR groups.
In plain wordsIn adults with type 2 diabetes, the inflammation marker MCP-1 fell after 3 months of liraglutide.
Peptide
Liraglutide
Outcome
DecreaseMCP-1 change
Study
n = 107
Comparator
Baseline (before treatment)
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
Compared with baseline, TNF-α, IL-6, MCP-1, and MDA were remarkably decreased, while SOD and glutathione peroxidase were significantly increased in all 3 groups (P < .05).
2 context sentences(design, population, supporting numbers)
Summary · context
We enrolled 107 patients with T2D who were initiating liraglutide for glycemic control.
Summary · context
Patients were categorized into 3 groups: group I (UACR 300 mg/g).
Report a problemFND-3980921208
09HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, the oxidative stress marker MDA fell significantly after 3 months of liraglutide in all 3 UACR groups.
In plain wordsIn adults with type 2 diabetes, the oxidative stress marker MDA fell after 3 months of liraglutide.
Peptide
Liraglutide
Outcome
DecreaseMDA change
Study
n = 107
Comparator
Baseline (before treatment)
Outcome group
Oxidative stress · Immune and inflammation
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
Compared with baseline, TNF-α, IL-6, MCP-1, and MDA were remarkably decreased, while SOD and glutathione peroxidase were significantly increased in all 3 groups (P < .05).
2 context sentences(design, population, supporting numbers)
Summary · context
We enrolled 107 patients with T2D who were initiating liraglutide for glycemic control.
Summary · context
Patients were categorized into 3 groups: group I (UACR 300 mg/g).
Report a problemFND-3980921209
10HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, superoxide dismutase rose significantly after 3 months of liraglutide in all 3 UACR groups.
In plain wordsIn adults with type 2 diabetes, the antioxidant enzyme SOD rose after 3 months of liraglutide.
Peptide
Liraglutide
Outcome
IncreaseSOD change
Study
n = 107
Comparator
Baseline (before treatment)
Outcome group
Oxidative stress · Immune and inflammation
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
Compared with baseline, TNF-α, IL-6, MCP-1, and MDA were remarkably decreased, while SOD and glutathione peroxidase were significantly increased in all 3 groups (P < .05).
2 context sentences(design, population, supporting numbers)
Summary · context
We enrolled 107 patients with T2D who were initiating liraglutide for glycemic control.
Summary · context
Patients were categorized into 3 groups: group I (UACR 300 mg/g).
Report a problemFND-3980921210
11HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, glutathione peroxidase rose significantly after 3 months of liraglutide in all 3 UACR groups.
In plain wordsIn adults with type 2 diabetes, the antioxidant enzyme glutathione peroxidase rose after 3 months of liraglutide.
Peptide
Liraglutide
Outcome
IncreaseGlutathione peroxidase change
Study
n = 107
Comparator
Baseline (before treatment)
Outcome group
Oxidative stress · Immune and inflammation
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
Compared with baseline, TNF-α, IL-6, MCP-1, and MDA were remarkably decreased, while SOD and glutathione peroxidase were significantly increased in all 3 groups (P < .05).
2 context sentences(design, population, supporting numbers)
Summary · context
We enrolled 107 patients with T2D who were initiating liraglutide for glycemic control.
Summary · context
Patients were categorized into 3 groups: group I (UACR 300 mg/g).
Report a problemFND-3980921211
12HumanObservational studyMechanism
In adults with type 2 diabetes on liraglutide, the change in UACR correlated with baseline UACR, TNF-α, MDA and SOD and with the change in MCP-1.
In plain wordsIn adults with type 2 diabetes on liraglutide, the change in urine albumin was linked to baseline inflammation and oxidative stress markers.
Peptide
Liraglutide
Outcome
Not applicableCorrelation of UACR change with baseline markers and MCP-1 change
Study
n = 107
Comparator
Baseline (before treatment)
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
The change in UACR was negatively correlated with UACR, TNF-α, and MDA at baseline, while it was positively correlated with SOD at baseline, and also positively correlated with the change in MCP-1.
2 context sentences(design, population, supporting numbers)
Summary · context
We enrolled 107 patients with T2D who were initiating liraglutide for glycemic control.
Summary · context
Patients were categorized into 3 groups: group I (UACR 300 mg/g).
Report a problemFND-3980921213

Studies that did not test the peptide alone1

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

13HumanNot a test of Liraglutide aloneObservational studyMechanism
In adults with type 2 diabetes, baseline UACR correlated positively with TNF-α, IL-6 and MDA and negatively with SOD before liraglutide.
In plain wordsIn adults with type 2 diabetes, before treatment, more urine albumin went with more inflammation and oxidative stress markers.
Peptide
Liraglutide
Outcome
Not applicableBaseline UACR correlation with inflammation and oxidative stress markers
Study
n = 107
Outcome group
Oxidative stress · Kidney and urinary
Source sentences
Summary
UACR at baseline showed a positive correlation with TNF-α, IL-6, and MDA, and a negative correlation with SOD at baseline.
2 context sentences(design, population, supporting numbers)
Summary · context
We enrolled 107 patients with T2D who were initiating liraglutide for glycemic control.
Summary · context
Patients were categorized into 3 groups: group I (UACR 300 mg/g).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3980921212

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.